Holen Sie sich die Stockscreener-App
67.57
0.40%
0.27
Vorhandelsmarkt:
65.22
-2.35
-3.48%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$67.30
Offen:
$68.04
24-Stunden-Volumen:
6.21M
Relative Volume:
1.09
Marktkapitalisierung:
$224.59B
Einnahmen:
$54.98B
Nettoeinkommen (Verlust:
$7.77B
KGV:
27.14
EPS:
2.49
Netto-Cashflow:
$9.14B
1W Leistung:
-6.72%
1M Leistung:
+1.21%
6M Leistung:
+4.78%
1J Leistung:
-12.94%
1-Tages-Spanne:
$67.52
$68.63
1-Wochen-Bereich:
$67.26
$72.69
52-Wochen-Spanne:
$61.24
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
67.57 | 224.59B | 54.98B | 7.77B | 9.14B | 2.49 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
AstraZeneca Loses Spot as UK’s Most Valuable Company to HSBC - Bloomberg.com
FTSE 100 LIVE: Stocks rise on US-China hopes, miners rally whilst AstraZeneca tumbles - Proactive financial news
GSK and Astrazeneca shares slump as Trump vows drug price cut - Yahoo
Trump's new pharma policy sends GSK and AstraZeneca shares tumbling - business-live.co.uk
FTSE 100 LIVE: Index starts higher, AstraZeneca and GSK hit by Trump social post - Proactive Investors
AstraZeneca (AZN) Faces Market Uncertainty Amid Drug Pricing Cha - GuruFocus
AstraZeneca PLC Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationAZN - ACCESS Newswire
AstraZeneca (AZN) Trial Reveals Promising Results for Bladder Ca - GuruFocus
AstraZeneca’s Imfinzi shows promise in bladder cancer trial By Investing.com - Investing.com UK
AstraZeneca posts positive data for Imfinzi in bladder cancer (AZN:NASDAQ) - Seeking Alpha
AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens By Stocktwits - Investing.com India
AstraZeneca (AZN) Trial Reveals Promising Results for Bladder Cancer Treatment | AZN Stock News - GuruFocus
AstraZeneca Pharma India gets CDSCO approval for Enhertu for new breast cancer indication - Medical Dialogues
AstraZeneca’s Imfinzi delays bladder cancer return in high-risk patients - Proactive Investors
AstraZeneca’s Imfinzi improves disease-free survival in high-risk NMIBC - DirectorsTalk Interviews
Astrazeneca Says Imfinzi Improved DFS In Early Bladder Cancer - marketscreener.com
Trump, Starmer hail limited US-UK trade deal, but 10% duties remain - marketscreener.com
AstraZeneca (AZN) Sees Increased Bullish Option Activity | AZN S - GuruFocus
US court shuts down AstraZeneca's challenge to Medicare drug price plan - Reuters
Investors who Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky About Pending Class ActionAZN - ACCESS Newswire
High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
June 27th Options Now Available For AstraZeneca - Nasdaq
AstraZeneca Loses Bid to Revive Drug Price Suit on Appeal (1) - Bloomberg Law News
Britain set to strike first deal to cut Trump tariffs - marketscreener.com
Does the GSK or AstraZeneca share price currently offer the best value? - MSN
AstraZeneca (AZN) Achieves Key Milestone with Enhertu in Breast Cancer Trial - GuruFocus
AstraZeneca marks Enhertu trial win in breast cancer (AZN) - Seeking Alpha
AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment - Yahoo Finance
AstraZeneca Says Enhertu Followed by THP Improved Pathologic Complete Response Rate in Breast Cancer Study - marketscreener.com
First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment - insights.citeline.com
ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Followed By THP Before Surgery Showed Statistically Significant And Clinically Meaningful Improvement In Pathologic Complete Response In High-Risk HER2-Positive Early-Stage Breast Cancer In DESTINY- - marketscreener.com
AstraZeneca (AZN) Sees Positive Results in DESTINY-Breast11 Trial | AZN Stock News - GuruFocus
AstraZeneca and GSK slide as Trump and RFK appoint new FDA vaccine chief - Proactive Investors
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model - Benzinga
Multiple System Atrophy (MSA) Market Research 2025-2035 - GlobeNewswire Inc.
AstraZeneca and GSK Share Price Slide as Markets React to Vinay Prasad’s FDA Appointment - paginasiete.bo
AstraZeneca plc (LON: AZN) Shares Fall 2.2% in Early Morning Trading - paginasiete.bo
REGAstraZeneca PLCEnhertu improved pCR in early-stage breast cancer - TradingView
AstraZeneca (AZN): Impact of FDA's New Inspection Strategy on Fo - GuruFocus
AstraZeneca unveils new factory as part of multibillion-dollar investment in US manufacturing - Yahoo Finance
AstraZeneca unveils $300M Rockville investment, a boost for MoCo amid federal cuts - The Business Journals
Berenberg: AstraZeneca, Eli Lilly Among Pharmaceutical Companies Set to Gain from US 'Pill Penalty' Update - marketscreener.com
AstraZeneca's (AZN) Calquence Gains EU Approval for Mantle Cell Lymphoma Treatment | AZN Stock News - GuruFocus
AstraZeneca's Calquence gets Europe approval for MCL - Sharecast.com
AstraZeneca Plc Calquence combo approved in EU for first-line MCL - DirectorsTalk Interviews
AstraZeneca's Calquence Regimen Wins EU Approval for Mantle Cell Lymphoma - marketscreener.com
AstraZeneca: EU Approves Calquence Combination For 1st-line Mantle Cell Lymphoma - Nasdaq
AstraZeneca Says Calquence Combination Approved In EU For 1L MCL - marketscreener.com
AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye - Yahoo Finance
Trump's Push for Lower Drug Prices Could Impact AstraZeneca (AZN - GuruFocus
Trump's Push for Lower Drug Prices Could Impact AstraZeneca (AZN) | AZN Stock News - GuruFocus
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):